Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Pulmonology Reports
Published in: Current Pulmonology Reports 4/2015

01-12-2015 | Bronchiectasis (G Tino, Section Editor)

Diagnostic approach to bronchiectasis

Authors: Daniel J. Dorgan, Gregory Tino, Anne O’Donnell

Published in: Current Pulmonology Reports | Issue 4/2015

Login to get access

Abstract

Bronchiectasis has been noted at increasing rates in recent years. It is associated with significant morbidity and mortality, although there is a wide range in the severity of bronchiectasis in different patients. There are many different potential causes of bronchiectasis. The aim of this review is to provide a structured approach to the clinical assessment of patients with known or suspected bronchiectasis, including evaluation of severity, airway microbiology, and potential causes of bronchiectasis. The discussion includes a rationale for each component of the diagnostic workup, including how certain diagnostic features can impact treatment, but this is not a comprehensive review of bronchiectasis treatment.
Literature
1.
2.
Seitz AE, Olivier KN, Adjemian J, et al. Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000 to 2007. Chest. 2012;142:432–9.PubMedCentralCrossRefPubMed
3.
Seitz AE, Olivier KN, Steiner CA, et al. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993–2006. Chest. 2010;138(4):944–9.PubMedCentralCrossRefPubMed
4.
Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005;12:205–9.CrossRef
5.
McShane PJ, Naureckas ET, Tino G, Strek ME. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013;188(6):647–56.CrossRefPubMed
6.••
Pasteur MC, Bilton D, Hill AT, et al. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65:i1–i58. This is the most comprehensive assessment to date of the evidence base for management of bronchiectasis, including grading of the evidence for all recommendations.CrossRefPubMed
7.
Onen ZP, Gulbay BE, Sen E, Yildiz OA, Saryal S, Acican T, et al. Analysis of the factors related to mortality in patients with bronchiectasis. Respir Med. 2007;101:1390–7.CrossRefPubMed
8.
Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J. 2009;34:843–9.CrossRefPubMed
9.•
Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index: an international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576–85. This study provides the most rigorous criteria for assessing the clinical severity of bronchiectasis. It is useful in the assessment of prognosis and when deciding treatment priorities in bronchiectasis.PubMedCentralCrossRefPubMed
10.
Tanaka E, Amitani R, Niimi A, et al. Yield of computed tomography and bronchoscopy for the diagnosis of Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med. 1997;155:2041–6.CrossRefPubMed
11.
Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416.CrossRefPubMed
12.
Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis. JAMA. 2013;309(12):1251–9.CrossRefPubMed
13.
Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis. JAMA. 2013;309(12):1260–7.CrossRefPubMed
14.
Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE). Lancet. 2012;380:660–67.CrossRefPubMed
15.••
Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. Respir Med. 2007;101:1163–70. This study is the largest studies assessing the underlying etiologies of bronchiectasis.CrossRefPubMed
16.••
Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000;162(4):1277–84. This study is the largest studies assessing the underlying etiologies of bronchiectasis. CrossRefPubMed
17.
McShane PJ, Naureckas ET, Strek ME. Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture. Chest. 2012;142:159–67.CrossRefPubMed
18.
Moore EH. Atypical mycobacterial infection in the lung: CT appearance. Radiology. 1993;187:777–82.CrossRefPubMed
19.
20.
Kartalija M, Ovrutsky AR, Bryan CL, Pott GB, Fantuzzi G, Thomas J, et al. Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. Am J Respir Crit Care Med. 2013;187:197–205.CrossRefPubMed
21.
Chan ED, Iseman MD. Underlying host risk factors for nontuberculous mycobacterial lung disease. Semin Respir Crit Care Med. 2013;34:110–23.CrossRefPubMed
22.
Cole PJ. Inflammation: a two-edged sword—the model of bronchiectasis. Eur J Respir Dis Suppl. 1986;147:6–15.PubMed
23.
Eijkhout HW, van Der Meer JW, Kallenberg CG, et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. Ann Intern Med. 2001;135:165–74.CrossRefPubMed
24.
Pifferi M, Di Cicco M, Bush A, et al. Uncommon pulmonary presentation of IgG 4-related disease in a 15-year-old boy. Chest. 2013;144(2):669–71.CrossRefPubMed
25.
CDC. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR 2006;55(No. RR-14).
26.
Chalmers JD, McHugh BJ, Doherty C, et al. Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study. Lancet Respir Med. 2013;1:224–32.CrossRefPubMed
27.
28.
Bienvenu T, Sermet-Gaudelus I, Burgel P-R, et al. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2010;181:1078–84.CrossRefPubMed
29.
Hubert D, Fajac I, Bienvenu T, et al. Diagnosis of cystic fibrosis in adults with diffuse bronchiectasis. J Cyst Fibros. 2004;3:15–22.CrossRefPubMed
30.
Stewart B, Zabner J, Shuber AP, et al. Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis. Am J Respir Crit Care Med. 1995;151:899–903.CrossRefPubMed
31.
Ramsey BW, Davies J, McElvaney MG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New Engl J Med. 2011;365:1663–72.PubMedCentralCrossRefPubMed
32.
Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. New Engl J Med. 2015;373:220–31.CrossRefPubMed
33.
Katsuhara K, Kawamoto S, Wakabayashi T, Belsky JL. Situs inversus totalis and Kartagener’s syndrome in a Japanese population. Chest. 1972;61(1):56–61.CrossRefPubMed
34.
35.
Shapiro AJ, Davis SD, Ferkol T, et al. Laterality defects other than situs inversus totalis in primary ciliary dyskinesia. Chest. 2014;146(5):1176–86.PubMedCentralCrossRefPubMed
36.
Leigh MW, Hazucha MJ, Chawla KK, et al. Standardizing nasal nitric oxide measurement as a test for primary ciliary dyskinesia. Ann Am Thorac Soc. 2013;10(6):574–81.PubMedCentralCrossRefPubMed
37.
Knowles MR, Daniels LA, Davis SD, et al. Primary ciliary dyskinesia. Recent advances in diagnostics, genetics, and characterization of clinical disease. Am J Respir Crit Care Med. 2013;188:913–22.PubMedCentralCrossRefPubMed
38.
Greenberger PA, Miller TP, Roberts M, et al. Allergic bronchopulmonary aspergillosis in patients with and without evidence of bronchiectasis. Ann Allergy. 1993;70:333–8.PubMed
39.
Rosenberg M, Patterson R, Mintzer R, et al. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med. 1977;86:405–14.CrossRefPubMed
40.
Angus RM, Davies ML, Cowan MD, et al. Computed tomographic scanning of the lung in patients with allergic bronchopulmonary aspergillosis and in asthmatic patients with a positive skin test to Aspergillus fumigatus. Thorax. 1994;49:586–9.PubMedCentralCrossRefPubMed
41.
Krustins E, Kravale Z, Buls A. Mounier-Kuhn syndrome or tracheobronchomegaly. Respir Med. 2013;107:1822–8.CrossRefPubMed
42.
Willams H, Campbell P. Generalized bronchiectasis associated with deficiency of cartilage in the bronchial tree. Arch Dis Child. 1960;35:182–91.CrossRef
43.
Demourelle MK, Weisman MH, Simonian PL, et al. Brief report: airways anomalies and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? Arthritis Rheum. 2012;64:1756–61.CrossRef
44.
Soto-Cardenas MJ, Perez-De-Lis M, Bove A, et al. Bronchiectasis in primary Sjogren’s syndrome: prevalence and clinical significance. Clin Exp Rheumatol. 2010;28:647–53.PubMed
45.
46.
47.
Ryu JH, Myers JL, Swensen SJ. Bronchiolar disorders. Am J Respir Crit Care Med. 2003;168:127–1292.CrossRef
48.
Martinez-Garcia M-A, de la Rosa CD, Soler-Cataluna J-J, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(8):823–31.CrossRefPubMed
49.
Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122.PubMedCentralPubMed
50.
Rasmussen JE, Sheridan JT, Polk W, et al. Cigarette smoke-induced Ca2+ release leads to cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction. J Biol Chem. 2014;289:7671–81.PubMedCentralCrossRefPubMed
Metadata
Title
Diagnostic approach to bronchiectasis
Authors
Daniel J. Dorgan
Gregory Tino
Anne O’Donnell
Publication date
01-12-2015
Publisher
Springer US
Published in
Current Pulmonology Reports / Issue 4/2015
Electronic ISSN: 2199-2428
DOI
https://doi.org/10.1007/s13665-015-0127-3

Other articles of this Issue 4/2015

Current Pulmonology Reports 4/2015 Go to the issue

Bronchiectasis (G Tino, Section Editor)

Inhaled antibiotics for bronchiectasis: are we there yet?

Smoking Cessation (S. Veeraraghavan, Section Editor)

Waterpipe tobacco-smoking: a new smoking epidemic among the young?

Smoking Cessation (S. Veeraraghavan, Section Editor)

Pharmacological therapies in smoking cessation: an evidence-based update

Smoking Cessation (S Veeraraghavan, Section Editor)

Computed tomography of smoking-related lung disease: review and update
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits